Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Palvella Therapeutics, Inc. (PVLA)
USD152.21
+2.53 (+1.69%)
US NASDAQ Healthcare Biotechnology
Address
125 Strafford Avenue 19087
Wayne, PA, US
Wayne, PA, US
CEO
Wesley H. Kaupinen
Website
palvellatx.com
IPO
2015-01-02
CIK 1583648 ISIN US6979471090
Description
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD152.21
+2.53 (+1.69%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
263.1K
Beta
-0.19
Float Shares
7.39M
Free Float %
62.5%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.03% | -2.53% | -1.05% | +53.37% | +54.27% | +20.18% | +506.22% | +639.94% | +639.94% | +639.94% | +639.94% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (10 ratings, all time)
Buy
Price Targets & DCF
Current price
152.21
Low
143.00
-6.1%
Consensus
205.15
+34.8%
Median
205.00
+34.7%
High
255.00
+67.5%
DCF (Unlevered)
4.71
-96.9%
DCF (Levered)
5.10
-96.7%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 15 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | 4 |
231.25
+51.9%
|
| Last Year | 29 |
158.17
+3.9%
|
| All Time | 31 |
150.39
-1.2%
|
Quality scores
Altman Z-Score
27.38
Safe zone
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
2 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+52.6% ★ Q1'26: +67.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +205.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+405.5% Q1'26: +487.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 9 Rev. Ana. 12 EPS Ana. |
Dec 2027 11 Rev. Ana. 9 EPS Ana. |
Dec 2028 10 Rev. Ana. 9 EPS Ana. |
Dec 2029 5 Rev. Ana. 3 EPS Ana. |
Dec 2030 5 Rev. Ana. 3 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.87M
est.
|
13.89M
est.
|
30.08M
est.
|
33.82M
est.
|
31.25M
est.
|
31.42M
est: 31.41M (+0.0%)
|
25.90M
est: 26.57M (-2.5%)
|
—
est: 31.98M (-100.0%)
|
—
est: 25.4K (-100.0%)
|
—
|
26.7K
11.8K – 57.4K
|
31.51M
16.18M – 65.71M
+118,045.6% YoY
|
140.60M
139.39M – 141.82M
+346.3% YoY
|
337.02M
149.04M – 725.22M
+139.7% YoY
|
706.35M
312.37M – 1.52B
+109.6% YoY
|
| EBITDA |
773.7K
est.
|
2.78M
est.
|
6.02M
est.
|
6.76M
est.
|
6.25M
est.
|
-43.37M
est: 6.28M (-790.4%)
|
-30.50M
est: 5.31M (-674.0%)
|
18.69M
est: 6.40M (+192.2%)
|
-13.12M
est: 5.1K (-258,614.0%)
|
-35.90M
|
5.3K
2.4K – 11.5K
|
6.30M
3.24M – 13.14M
+118,054.5% YoY
|
28.12M
27.88M – 28.36M
+346.3% YoY
|
67.40M
29.81M – 145.04M
+139.7% YoY
|
141.27M
62.47M – 303.99M
+109.6% YoY
|
| EBIT |
773.7K
est.
|
2.78M
est.
|
6.02M
est.
|
6.76M
est.
|
6.25M
est.
|
-45.74M
est: 6.28M (-828.1%)
|
-33.28M
est: 5.31M (-726.3%)
|
18.69M
est: 6.40M (+192.2%)
|
-13.12M
est: 5.1K (-258,614.0%)
|
-35.90M
|
5.3K
2.4K – 11.5K
|
6.30M
3.24M – 13.14M
+118,054.5% YoY
|
28.12M
27.88M – 28.36M
+346.3% YoY
|
67.40M
29.81M – 145.04M
+139.7% YoY
|
141.27M
62.47M – 303.99M
+109.6% YoY
|
| Net Income |
-95.57M
est.
|
-114.42M
est.
|
-85.03M
est.
|
-135.34M
est.
|
-117.53M
est.
|
-45.74M
est: -125.55M (+63.6%)
|
-33.28M
est: -112.96M (+70.5%)
|
18.69M
est: -62.33M (+130.0%)
|
-17.43M
est: -31.93M (+45.4%)
|
-41.72M
est: -37.19M (-12.2%)
|
-75.63M
-80.59M – -40.42M
-103.4% YoY
|
-109.74M
-118.02M – -48.04M
-45.1% YoY
|
-49.45M
-103.00M – 92.59M
+54.9% YoY
|
58.99M
16.22M – 147.31M
+219.3% YoY
|
225.01M
61.86M – 561.95M
+281.5% YoY
|
| SGA |
3.22M
est.
|
11.56M
est.
|
25.04M
est.
|
28.16M
est.
|
26.02M
est.
|
16.68M
est: 26.15M (-36.2%)
|
16.38M
est: 22.12M (-25.9%)
|
3.08M
est: 26.63M (-88.4%)
|
5.94M
est: 21.1K (+28,030.6%)
|
15.76M
|
22.2K
9.8K – 47.8K
|
26.24M
13.47M – 54.72M
+118,050.9% YoY
|
117.08M
116.07M – 118.09M
+346.3% YoY
|
280.64M
124.11M – 603.90M
+139.7% YoY
|
588.18M
260.11M – 1.27B
+109.6% YoY
|
| EPS |
-42.93
est.
|
-51.40
est.
|
-38.20
est.
|
-60.80
est.
|
-52.80
est.
|
-56.69
est: -56.40 (-0.5%)
|
-29.61
est: -50.74 (+41.6%)
|
14.74
est: -28.00 (+152.6%)
|
-7.83
est: -2.84 (-175.5%)
|
-3.71
est: -3.52 (-5.5%)
|
-5.55
-7.16 – -3.59
-57.7% YoY
|
-6.52
-10.49 – -4.27
-17.4% YoY
|
-2.58
-9.15 – 8.23
+60.4% YoY
|
5.24
1.44 – 13.09
+303.3% YoY
|
20.00
5.50 – 49.95
+281.5% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 2/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-05 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-01 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | C- | 1/5 | 2/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-25.01M
OE per share TTM
-4.68
Owner's Yield
-1.71%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
41.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
26
Total invested
29.50M
Insider transactions (90d)
0
Beneficial owners (>5%)
16
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Checkpoint Capital (Master) Fund, LP | 4.94M | 6.00% | — | 4.94M | — | — | PN | Delaware | 2023-06-12 | ↗ |
| 2 | Checkpoint Capital, LP | 4.94M | 6.00% | — | 4.94M | — | — | IA, HC | Delaware | 2023-06-12 | ↗ |
| 3 | Sam Huang | 4.94M | 6.00% | — | 4.94M | — | — | HC, IN | Delaware | 2023-06-12 | ↗ |
| 4 | BVF Inc. | 257.6K | 19.50% | — | — | — | 257.6K | CO | Delaware | 2024-05-17 | ↗ |
| 5 | BVF Partners L.P. | 257.6K | 19.50% | — | — | — | 257.6K | IA, PN | Delaware | 2024-05-17 | ↗ |
| 6 | Mark N. Lampert | 257.6K | 19.50% | — | — | — | 257.6K | IN | Delaware | 2024-05-17 | ↗ |
| 7 | BVF GP Holdings LLC | 244.9K | 18.50% | — | — | — | 244.9K | OO | Delaware | 2024-05-17 | ↗ |
| 8 | ADAR1 Capital Management GP, LLC | 138.6K | 10.50% | — | 138.6K | — | 138.6K | OO | Texas | 2024-08-01 | ↗ |
| 9 | ADAR1 Capital Management, LLC | 138.6K | 10.50% | — | 138.6K | — | 138.6K | IA | Texas | 2024-08-01 | ↗ |
| 10 | Daniel Schneeberger | 138.6K | 10.50% | — | 138.6K | — | 138.6K | IN | Texas | 2024-08-01 | ↗ |
| 11 | BVF I GP LLC | 137.6K | 10.40% | — | — | — | 137.6K | OO | Delaware | 2024-05-17 | ↗ |
| 12 | Biotechnology Value Fund, L.P. | 137.6K | 10.40% | — | — | — | 137.6K | PN | Delaware | 2024-05-17 | ↗ |
| 13 | BVF II GP LLC | 107.3K | 8.10% | — | — | — | 107.3K | OO | Delaware | 2024-05-17 | ↗ |
| 14 | Biotechnology Value Fund II, L.P. | 107.3K | 8.10% | — | — | — | 107.3K | PN | Delaware | 2024-05-17 | ↗ |
| 15 | BVF Partners OS Ltd. | 9.3K | 1.00% | — | — | — | 9.3K | CO | Delaware | 2024-05-17 | ↗ |
| 16 | Biotechnology Value Trading Fund OS LP | 9.3K | 1.00% | — | — | — | 9.3K | PN | Delaware | 2024-05-17 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
26
-121 vs prev Q
New positions
7
Closed positions
126
Increased
14
Reduced
6
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 82.7K +82.7K (+100.0%) | 8.65B +8.7B (+100.0%) | 0.75% +0.747 pp | 5.08% +5.076 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 2 | SUVRETTA CAPITAL MANAGEMENT, LLC | 892.4K +70.0K (+8.5%) | 93.41M +41.9M (+81.2%) | 8.07% +0.625 pp | 1.91% +0.594 pp | USD25.40 +312.1% | 5 qtrs — |
| 3 | BVF INC/IL | 879.0K -282.2K (-24.3%) | 92.01M +19.2M (+26.4%) | 7.94% -2.562 pp | 3.10% +0.146 pp | USD32.28 +224.3% | 5 qtrs — |
| 4 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 722.4K +— (+0.0%) | 75.61M +30.3M (+67.0%) | 6.53% -0.007 pp | 2.03% +0.674 pp | USD13.27 +688.8% | 5 qtrs — |
| 5 | FIRST LIGHT ASSET MANAGEMENT, LLC | 709.1K +167.6K (+30.9%) | 74.23M +40.3M (+118.6%) | 6.41% +1.510 pp | 5.67% +2.475 pp | USD72.61 +44.2% | 2 qtrs — |
| 6 | VANGUARD GROUP INC | 560.6K +66.0K (+13.3%) | 58.68M +27.7M (+89.2%) | 5.07% +0.592 pp | 0.00% +0.000 pp | USD56.92 +83.9% | 5 qtrs — |
| 7 | BLACKROCK, INC. | 559.1K +71.4K (+14.7%) | 58.52M +27.9M (+91.4%) | 5.05% +0.641 pp | 0.00% +0.001 pp | USD36.80 +184.4% | 5 qtrs — |
| 8 | STATE STREET CORP | 420.5K +283.2K (+206.3%) | 44.01M +35.4M (+411.5%) | 3.80% +2.558 pp | 0.00% +0.001 pp | USD83.29 +25.7% | 4 qtrs — |
| 9 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 389.4K +354.5K (+1,016.0%) | 40.76M +38.6M (+1,763.3%) | 3.52% +3.204 pp | 0.85% +0.802 pp | USD100.91 +3.7% | 2 qtrs — |
| 10 | JENNISON ASSOCIATES LLC | 387.5K +280.6K (+262.4%) | 40.56M +33.9M (+505.1%) | 3.50% +2.535 pp | 0.02% +0.020 pp | USD93.09 +12.4% | 2 qtrs — |
| 11 | FEDERATED HERMES, INC. | 368.0K +29.0K (+8.6%) | 38.52M +17.3M (+81.2%) | 3.33% +0.259 pp | 0.06% +0.027 pp | USD66.00 +58.6% | 2 qtrs — |
| 12 | WOODLINE PARTNERS LP | 300.5K -45.2K (-13.1%) | 31.46M +9.8M (+45.1%) | 2.72% -0.412 pp | 0.12% +0.020 pp | USD24.91 +320.2% | 4 qtrs — |
| 13 | ALLIANCEBERNSTEIN L.P. | 269.0K +269.0K (+100.0%) | 28.16M +28.2M (+100.0%) | 2.43% +2.432 pp | 0.01% +0.009 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 14 | PERCEPTIVE ADVISORS LLC | 266.3K -128.8K (-32.6%) | 27.87M +3.1M (+12.5%) | 2.41% -1.168 pp | 0.50% -0.218 pp | USD62.69 +67.0% | 2 qtrs — |
| 15 | FMR LLC | 231.8K +121.3K (+109.8%) | 24.26M +17.3M (+250.4%) | 2.09% +1.095 pp | 0.00% +0.001 pp | USD84.65 +23.7% | 3 qtrs — |
| 16 | MORGAN STANLEY | 220.7K +82.2K (+59.3%) | 23.10M +14.4M (+166.0%) | 1.99% +0.741 pp | 0.00% +0.001 pp | USD53.86 +94.3% | 5 qtrs — |
| 17 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 211.6K +211.6K (+100.0%) | 22.14M +22.1M (+100.0%) | 1.91% +1.912 pp | 0.03% +0.033 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 18 | BIOIMPACT CAPITAL LLC | 205.7K +138.3K (+205.2%) | 21.54M +17.3M (+409.5%) | 1.86% +1.250 pp | 2.46% +1.772 pp | USD90.91 +15.1% | 2 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 179.0K +10.9K (+6.5%) | 18.74M +8.2M (+77.8%) | 1.62% +0.097 pp | 0.00% +0.001 pp | USD29.07 +260.1% | 5 qtrs — |
| 20 | FRED ALGER MANAGEMENT, LLC | 150.0K -36.7K (-19.7%) | 15.70M +4.0M (+34.1%) | 1.36% -0.334 pp | 0.06% +0.016 pp | USD59.78 +75.1% | 3 qtrs — |
| 21 | BALYASNY ASSET MANAGEMENT L.P. | 108.9K -57.7K (-34.6%) | 11.40M +956.4K (+9.2%) | 0.98% -0.523 pp | 0.01% +0.001 pp | USD62.69 +67.0% | 4 qtrs — |
| 22 | SAMSARA BIOCAPITAL, LLC | 104.8K -104.8K (-50.0%) | 10.97M -2.2M (-16.5%) | 0.95% -0.949 pp | 1.13% -0.584 pp | USD12.00 +772.3% | 5 qtrs — |
| 23 | EVENTIDE ASSET MANAGEMENT, LLC | 101.7K +101.7K (+100.0%) | 10.65M +10.6M (+100.0%) | 0.92% +0.920 pp | 0.17% +0.166 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 24 | GOLDMAN SACHS GROUP INC | 98.9K -137.7K (-58.2%) | 10.36M -4.5M (-30.2%) | 0.89% -1.247 pp | 0.00% -0.001 pp | USD48.65 +115.1% | 4 qtrs — |
| 25 | CAPTION MANAGEMENT, LLC | 95.3K +95.3K (+100.0%) | 9.98M +10.0M (+100.0%) | 0.86% +0.861 pp | 0.07% +0.068 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 26 | CLIO ASSET MANAGEMENT LLC | 91.6K +1.0 (+0.0%) | 9.59M +3.8M (+67.0%) | 0.83% -0.001 pp | 7.45% +3.185 pp | USD22.60 +363.1% | 3 qtrs — |
| 27 | POINT72 ASSET MANAGEMENT, L.P. | 77.3K -240.0K (-75.6%) | 8.09M -11.8M (-59.3%) | 0.70% -2.172 pp | 0.01% -0.024 pp | USD62.69 +67.0% | 2 qtrs — |
| 28 | SIREN, L.L.C. | 75.0K +75.0K (+100.0%) | 7.85M +7.9M (+100.0%) | 0.68% +0.678 pp | 0.23% +0.234 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 29 | AWM INVESTMENT COMPANY, INC. | 69.4K +— (+0.0%) | 7.27M +2.9M (+67.0%) | 0.63% -0.001 pp | 0.70% +0.294 pp | USD27.99 +274.0% | 4 qtrs — |
| 30 | CLEARBRIDGE INVESTMENTS, LLC | 60.6K +60.6K (+100.0%) | 6.35M +6.3M (+100.0%) | 0.55% +0.548 pp | 0.01% +0.005 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 31 | ARTIA GLOBAL PARTNERS LP | 59.2K +59.2K (+100.0%) | 6.20M +6.2M (+100.0%) | 0.54% +0.535 pp | 0.99% +0.988 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 32 | NORTHERN TRUST CORP | 54.5K +487.0 (+0.9%) | 5.70M +2.3M (+68.5%) | 0.49% +0.004 pp | 0.00% +0.000 pp | USD24.92 +320.0% | 4 qtrs — |
| 33 | INVESCO LTD. | 54.3K +5.7K (+11.6%) | 5.68M +2.6M (+86.4%) | 0.49% +0.051 pp | 0.00% +0.000 pp | USD67.07 +56.1% | 2 qtrs — |
| 34 | UBS ASSET MANAGEMENT AMERICAS INC | 47.7K +47.7K (+100.0%) | 4.99M +5.0M (+100.0%) | 0.43% +0.431 pp | 0.00% +0.001 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 35 | NEUBERGER BERMAN GROUP LLC | 44.9K +44.9K (+100.0%) | 4.70M +4.7M (+100.0%) | 0.41% +0.406 pp | 0.00% +0.004 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 36 | LISANTI CAPITAL GROWTH, LLC | 41.5K +41.5K (+100.0%) | 4.34M +4.3M (+100.0%) | 0.37% +0.375 pp | 1.03% +1.028 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 37 | BLUE OWL CAPITAL HOLDINGS LP | 40.3K -55.0K (-57.7%) | 4.21M -1.8M (-29.4%) | 0.36% -0.498 pp | 0.32% -1.539 pp | USD12.00 +772.3% | 5 qtrs — |
| 38 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 38.2K +22.5K (+143.3%) | 4.00M +3.0M (+306.2%) | 0.35% +0.203 pp | 0.00% +0.000 pp | USD77.01 +35.9% | 3 qtrs — |
| 39 | UBS GROUP AG | 36.5K +16.1K (+78.6%) | 3.82M +2.5M (+198.2%) | 0.33% +0.145 pp | 0.00% +0.000 pp | USD59.35 +76.4% | 5 qtrs — |
| 40 | BANK OF AMERICA CORP /DE/ | 30.3K +25.6K (+545.6%) | 3.17M +2.9M (+977.9%) | 0.27% +0.231 pp | 0.00% +0.000 pp | USD93.38 +12.1% | 5 qtrs — |
| 41 | ROYCE & ASSOCIATES LP | 30.0K -19.5K (-39.4%) | 3.14M +37.4K (+1.2%) | 0.27% -0.177 pp | 0.03% +0.001 pp | USD27.77 +276.9% | 4 qtrs — |
| 42 | SUPERSTRING CAPITAL MANAGEMENT LP | 25.5K +25.5K (+100.0%) | 2.67M +2.7M (+100.0%) | 0.23% +0.230 pp | 1.43% +1.427 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 43 | BARCLAYS PLC | 25.1K +15.4K (+157.1%) | 2.63M +2.0M (+329.3%) | 0.23% +0.139 pp | 0.00% +0.001 pp | USD72.71 +44.0% | 5 qtrs — |
| 44 | JANE STREET GROUP, LLC | 24.0K +24.0K (+100.0%) | 2.51M +2.5M (+100.0%) | 0.22% +0.217 pp | 0.00% +0.000 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 45 | RENAISSANCE TECHNOLOGIES LLC | 22.5K -67.2K (-74.9%) | 2.36M -3.3M (-58.1%) | 0.20% -0.608 pp | 0.00% -0.004 pp | USD30.97 +238.0% | 5 qtrs — |
| 46 | SIG BROKERAGE, LP | 22.5K +22.5K (+100.0%) | 2.36M +2.4M (+100.0%) | 0.20% +0.203 pp | 0.07% +0.073 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 47 | WELLINGTON MANAGEMENT GROUP LLP | 22.4K -1.3K (-5.5%) | 2.34M +859.0K (+57.8%) | 0.20% -0.012 pp | 0.00% +0.000 pp | USD62.69 +67.0% | 2 qtrs — |
| 48 | RAYMOND JAMES FINANCIAL INC | 22.3K -1.6K (-6.6%) | 2.33M +836.0K (+55.9%) | 0.20% -0.015 pp | 0.00% +0.000 pp | USD62.68 +67.0% | 3 qtrs — |
| 49 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 21.6K +620.0 (+3.0%) | 2.26M +947.0K (+71.9%) | 0.20% +0.005 pp | 0.00% +0.000 pp | USD24.89 +320.5% | 3 qtrs — |
| 50 | NUVEEN, LLC | 19.6K +6.9K (+54.1%) | 2.05M +1.3M (+157.3%) | 0.18% +0.062 pp | 0.00% +0.000 pp | USD59.16 +76.9% | 3 qtrs — |
| 51 | AVIDITY PARTNERS MANAGEMENT LP | 19.3K +19.3K (+100.0%) | 2.02M +2.0M (+100.0%) | 0.17% +0.174 pp | 0.58% +0.583 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 52 | NEW YORK STATE COMMON RETIREMENT FUND | 17.3K +14.5K (+518.4%) | 1.81M +1.6M (+932.5%) | 0.16% +0.131 pp | 0.00% +0.002 pp | USD91.39 +14.5% | 3 qtrs — |
| 53 | BANK OF NEW YORK MELLON CORP | 16.3K +79.0 (+0.5%) | 1.70M +687.7K (+67.8%) | 0.15% +0.001 pp | 0.00% +0.000 pp | USD29.17 +258.8% | 3 qtrs — |
| 54 | RAFFERTY ASSET MANAGEMENT, LLC | 15.7K +15.7K (+100.0%) | 1.65M +1.6M (+100.0%) | 0.14% +0.142 pp | 0.01% +0.006 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 55 | SWISS NATIONAL BANK | 14.2K +14.2K (+100.0%) | 1.49M +1.5M (+100.0%) | 0.13% +0.128 pp | 0.00% +0.001 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 56 | VICTORY CAPITAL MANAGEMENT INC | 14.1K +14.1K (+100.0%) | 1.48M +1.5M (+100.0%) | 0.13% +0.128 pp | 0.00% +0.001 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 57 | TUDOR INVESTMENT CORP ET AL | 12.5K +12.5K (+100.0%) | 1.31M +1.3M (+100.0%) | 0.11% +0.113 pp | 0.00% +0.002 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 58 | VERITION FUND MANAGEMENT LLC | 11.9K +11.9K (+100.0%) | 1.25M +1.2M (+100.0%) | 0.11% +0.108 pp | 0.00% +0.005 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 59 | SEI INVESTMENTS CO | 11.7K +11.7K (+100.0%) | 1.23M +1.2M (+100.0%) | 0.11% +0.106 pp | 0.00% +0.001 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 60 | MARINER, LLC | 11.6K -9.1K (-43.9%) | 1.22M -83.3K (-6.4%) | 0.11% -0.083 pp | 0.00% 0.000 pp | USD62.69 +67.0% | 2 qtrs — |
| 61 | CRESSET ASSET MANAGEMENT, LLC | 11.4K -6.0K (-34.4%) | 1.20M +104.0K (+9.5%) | 0.10% -0.054 pp | 0.01% +0.000 pp | USD12.00 +772.3% | 5 qtrs — |
| 62 | LEGATO CAPITAL MANAGEMENT LLC | 11.4K +11.4K (+100.0%) | 1.19M +1.2M (+100.0%) | 0.10% +0.103 pp | 0.10% +0.103 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 63 | WELLS FARGO & COMPANY/MN | 10.9K +3.6K (+48.8%) | 1.14M +683.3K (+148.4%) | 0.10% +0.032 pp | 0.00% +0.000 pp | USD62.94 +66.3% | 5 qtrs — |
| 64 | CATALIO CAPITAL MANAGEMENT, LP | 10.5K -1.6K (-13.0%) | 1.09M +341.1K (+45.3%) | 0.09% -0.014 pp | 0.19% +0.054 pp | USD62.69 +67.0% | 2 qtrs — |
| 65 | ALPS ADVISORS INC | 9.7K +4.2K (+77.1%) | 1.02M +673.1K (+195.7%) | 0.09% +0.038 pp | 0.01% +0.004 pp | USD80.97 +29.3% | 2 qtrs — |
| 66 | MARSHALL WACE, LLP | 9.5K +9.5K (+100.0%) | 992.7K +992.7K (+100.0%) | 0.09% +0.086 pp | 0.00% +0.001 pp | USD104.67 +0.0% | 4 qtrs — |
| 67 | CINCTIVE CAPITAL MANAGEMENT LP | 8.7K +8.7K (+100.0%) | 911.4K +911.4K (+100.0%) | 0.08% +0.079 pp | 0.05% +0.049 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 68 | RHUMBLINE ADVISERS | 8.6K -1.2K (-12.5%) | 903.9K +285.1K (+46.1%) | 0.08% -0.011 pp | 0.00% +0.000 pp | USD22.54 +364.4% | 3 qtrs — |
| 69 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 6.9K +6.5K (+1,512.8%) | 724.2K +697.3K (+2,592.8%) | 0.06% +0.059 pp | 0.00% +0.001 pp | USD99.58 +5.1% | 3 qtrs — |
| 70 | DEUTSCHE BANK AG\ | 6.6K +528.0 (+8.7%) | 690.2K +309.9K (+81.5%) | 0.06% +0.005 pp | 0.00% +0.000 pp | USD29.12 +259.4% | 3 qtrs — |
| 71 | SIGMA PLANNING CORP | 6.5K +6.5K (+100.0%) | 680.4K +680.4K (+100.0%) | 0.06% +0.059 pp | 0.02% +0.019 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 72 | BROWN ADVISORY INC | 6.4K +— (+0.0%) | 667.7K +267.8K (+67.0%) | 0.06% 0.000 pp | 0.00% +0.000 pp | USD62.69 +67.0% | 2 qtrs — |
| 73 | ASPIRIANT, LLC | 5.9K +— (+0.0%) | 612.5K +245.7K (+67.0%) | 0.05% 0.000 pp | 0.02% +0.006 pp | USD62.69 +67.0% | 2 qtrs — |
| 74 | LEGAL & GENERAL GROUP PLC | 5.8K +5.1K (+674.7%) | 612.2K +564.9K (+1,193.5%) | 0.05% +0.046 pp | 0.00% +0.000 pp | USD94.07 +11.3% | 3 qtrs — |
| 75 | PROFUND ADVISORS LLC | 5.8K +5.8K (+100.0%) | 608.4K +608.4K (+100.0%) | 0.05% +0.053 pp | 0.02% +0.019 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 76 | BREVAN HOWARD CAPITAL MANAGEMENT LP | 5.7K +5.7K (+100.0%) | 584.6K +584.6K (+100.0%) | 0.05% +0.052 pp | 0.01% +0.006 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 77 | JPMORGAN CHASE & CO | 5.0K +668.0 (+15.4%) | 524.0K +252.0K (+92.7%) | 0.05% +0.006 pp | 0.00% +0.000 pp | USD42.26 +147.7% | 5 qtrs — |
| 78 | FRANKLIN RESOURCES INC | 4.7K +— (+0.0%) | 486.7K +195.2K (+67.0%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD62.69 +67.0% | 2 qtrs — |
| 79 | STATE OF WISCONSIN INVESTMENT BOARD | 4.5K +4.5K (+100.0%) | 472.4K +472.4K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.001 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 80 | MIRAE ASSET GLOBAL ETFS HOLDINGS LTD. | 4.3K +1.1K (+35.7%) | 446.3K +247.3K (+124.3%) | 0.04% +0.010 pp | 0.00% +0.000 pp | USD44.13 +137.2% | 3 qtrs — |
| 81 | METLIFE INVESTMENT MANAGEMENT, LLC | 4.3K +— (+0.0%) | 445.9K +178.8K (+67.0%) | 0.04% +0.000 pp | 0.00% +0.001 pp | USD22.54 +364.4% | 3 qtrs — |
| 82 | XTX TOPCO LTD | 4.1K +4.1K (+100.0%) | 429.5K +429.5K (+100.0%) | 0.04% +0.037 pp | 0.01% +0.011 pp | USD104.67 +0.0% | 3 qtrs — |
| 83 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.1K +433.0 (+11.8%) | 429.0K +199.0K (+86.5%) | 0.04% +0.004 pp | 0.00% +0.000 pp | USD67.13 +55.9% | 2 qtrs — |
| 84 | TWO SIGMA INVESTMENTS, LP | 4.1K +— (+0.0%) | 428.1K +171.7K (+67.0%) | 0.04% +0.000 pp | 0.00% +0.000 pp | USD62.69 +67.0% | 2 qtrs — |
| 85 | JANUS HENDERSON GROUP PLC | 3.6K +3.6K (+100.0%) | 376.2K +376.2K (+100.0%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 86 | LETKO, BROSSEAU & ASSOCIATES INC | 3.5K -1.7K (-32.7%) | 366.3K +40.4K (+12.4%) | 0.03% -0.015 pp | 0.01% +0.000 pp | USD62.69 +67.0% | 2 qtrs — |
| 87 | MILLENNIUM MANAGEMENT LLC | 3.5K -23.4K (-87.1%) | 364.3K -1.3M (-78.4%) | 0.03% -0.212 pp | 0.00% -0.001 pp | USD27.21 +284.7% | 4 qtrs — |
| 88 | INTECH INVESTMENT MANAGEMENT LLC | 3.5K -659.0 (-16.0%) | 363.1K +104.3K (+40.3%) | 0.03% -0.006 pp | 0.00% +0.001 pp | USD62.69 +67.0% | 2 qtrs — |
| 89 | LPL FINANCIAL LLC | 3.4K +3.4K (+100.0%) | 360.9K +360.9K (+100.0%) | 0.03% +0.031 pp | 0.00% +0.000 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 90 | BAADER BANK AKTIENGESELLSCHAFT | 3.1K +3.1K (+100.0%) | 326.5K +326.5K (+100.0%) | 0.03% +0.028 pp | 0.02% +0.022 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 91 | CERTUITY, LLC | 3.0K +3.0K (+100.0%) | 314.0K +314.0K (+100.0%) | 0.03% +0.027 pp | 0.02% +0.020 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 92 | PEAPACK GLADSTONE FINANCIAL CORP | 3.0K +3.0K (+100.0%) | 314.0K +314.0K (+100.0%) | 0.03% +0.027 pp | 0.00% +0.004 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 93 | CREATIVE PLANNING | 3.0K +3.0K (+100.0%) | 310.1K +310.1K (+100.0%) | 0.03% +0.027 pp | 0.00% +0.000 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 94 | QUEST PARTNERS LLC | 2.8K +137.0 (+5.2%) | 288.3K +124.2K (+75.7%) | 0.02% +0.001 pp | 0.02% +0.005 pp | USD64.78 +61.6% | 2 qtrs — |
| 95 | VIRTUS INVESTMENT ADVISERS, INC. | 2.7K +2.7K (+100.0%) | 282.4K +282.4K (+100.0%) | 0.02% +0.024 pp | 0.08% +0.077 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 96 | SG AMERICAS SECURITIES, LLC | 2.7K +2.7K (+100.0%) | 281.0K +281.0K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 97 | CITADEL ADVISORS LLC | 2.6K +2.6K (+100.0%) | 275.9K +275.9K (+100.0%) | 0.02% +0.024 pp | 0.00% +0.000 pp | USD104.67 +0.0% | 1 qtrs NEW |
| 98 | CHUNG WU INVESTMENT GROUP, LLC | 2.6K +2.4K (+1,200.0%) | 272.1K +259.6K (+2,070.5%) | 0.02% +0.022 pp | 0.22% +0.212 pp | USD101.44 +3.2% | 2 qtrs — |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 78 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | F/M Emerald Life Sciences Innovation ETF LFSC | 2.02% | 1.51M | 0.54% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 1.05% | 2.24M | 0.50% |
| 3 | Virtus Biotech Clinical Trials ETF BBC | 0.82% | 471.4K | 0.65% |
| 4 | Global X - S&P Biotech ETF CURE.AX | 0.55% | 197.5K | 0.45% |
| 5 | State Street SPDR S&P Biotech ETF XBI | 0.55% | 59.32M | 0.35% |
| 6 | Vanguard U.S. Momentum Factor ETF VFMO | 0.15% | 2.48M | 0.13% |
| 7 | Vanguard Global Momentum Factor ETF VMO.TO | 0.12% | 439.5K | 0.38% |
| 8 | Pacer WealthShield ETF PWS | 0.11% | 27.5K | 0.60% |
| 9 | T. Rowe Price Innovation Leaders ETF TNXT | 0.10% | 18.2K | 0.49% |
| 10 | iShares Russell 2000 Growth ETF IWO | 0.10% | 14.70M | 0.24% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.43
Bearish
Ratio by volume
1.20
Neutral
Buys
3
Sells
7
Shares acquired
10.3K
Shares disposed
8.6K
Cash buys
—
Cash sales
5.00
Net activity
+1,698
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-15 | Goin Kathleen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,154 | 7.14 | 15.4K | 12,935 | D | ↗ |
| 2026-04-13 | Doux John | Director | — | — | Stock Option (Right to Buy) | 10,364 | 7.14 | 74.0K | 0 | D | ↗ |
| 2026-03-30 | JENKINS GEORGE M | Director | P-Purchase | A | Common Stock | 445 | 112.30 | 50.0K | 187,616 | D | ↗ |
| 2026-03-18 | Goin Kathleen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,154 | 7.14 | 15.4K | 15,089 | D | ↗ |
| 2026-02-27 | JENKINS GEORGE M | Director | P-Purchase | A | Common Stock | 4,000 | 125.00 | 500.0K | 187,171 | D | ↗ |
| 2026-02-27 | HERON ELAINE J | Director | P-Purchase | A | Common Stock | 2,400 | 125.00 | 300.0K | 47,812 | D | ↗ |
| 2026-02-18 | Goin Kathleen | Officer | M-Exempt | A | Common Stock | 2,148 | 9.08 | 19.5K | 4,302 | D | ↗ |
| 2026-02-05 | Martini Jeffrey S | Officer | A-Award | A | Stock Option (Right to Buy) | 64,318 | 76.43 | 4.92M | 64,318 | D | ↗ |
| 2026-02-05 | Korenberg Matthew E | Officer | A-Award | A | Stock Option (Right to Buy) | 44,123 | 76.43 | 3.37M | 44,123 | D | ↗ |
| 2026-02-05 | Kline Ashley Hartmann | Officer | A-Award | A | Stock Option (Right to Buy) | 38,517 | 76.43 | 2.94M | 38,517 | D | ↗ |
| 2026-02-05 | Kaupinen Wes | Director / Officer / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 124,603 | 76.43 | 9.52M | 124,603 | D | ↗ |
| 2026-02-05 | Goin Kathleen | Officer | A-Award | A | Stock Option (Right to Buy) | 48,956 | 76.43 | 3.74M | 48,956 | D | ↗ |
| 2026-01-21 | Goin Kathleen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,154 | 7.14 | 15.4K | 19,397 | D | ↗ |
| 2025-12-17 | Goin Kathleen | Officer | M-Exempt | A | Common Stock | 2,148 | 9.08 | 19.5K | 4,302 | D | ↗ |
| 2025-11-19 | Goin Kathleen | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,154 | 7.14 | 15.4K | 23,705 | D | ↗ |
| 2025-06-10 | Wessel Tadd S. | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,350 | 26.23 | 323.9K | 12,350 | D | ↗ |
| 2025-06-10 | KIRITSY CHRISTOPHER P | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,350 | 26.23 | 323.9K | 12,350 | D | ↗ |
| 2025-06-10 | JENKINS GEORGE M | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,350 | 26.23 | 323.9K | 12,350 | D | ↗ |
| 2025-06-10 | HERON ELAINE J | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,350 | 26.23 | 323.9K | 12,350 | D | ↗ |
| 2025-06-10 | Davis Todd C | Director | A-Award | A | Non-Qualified Stock Option (right to buy) | 12,350 | 26.23 | 323.9K | 12,350 | D | ↗ |
| 2025-05-27 | Kline Ashley Hartmann | Officer | A-Award | A | Incentive Stock Option (right to buy) | 17,436 | 22.94 | 400.0K | 17,436 | D | ↗ |
| 2025-04-09 | JENKINS GEORGE M | Director | P-Purchase | A | Common Stock | 2,500 | 20.13 | 50.3K | 183,171 | D | ↗ |
| 2025-02-05 | PALVELLA THERAPEUTICS, INC. | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 243,831 | 14.76 | 3.60M | 243,831 | D | ↗ |
| 2025-02-05 | Martini Jeffrey S | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 123,559 | 14.76 | 1.82M | 123,559 | D | ↗ |
| 2025-02-05 | Korenberg Matthew E | Officer | A-Award | A | Incentive Stock Option (right to buy) | 5,373 | 14.76 | 79.3K | 5,373 | D | ↗ |
| 2025-02-05 | Kaupinen Wes | Director / Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 243,831 | 14.76 | 3.60M | 243,831 | D | ↗ |
| 2025-02-05 | Goin Kathleen | Officer | A-Award | A | Non-Qualified Stock Option (right to buy) | 123,559 | 14.76 | 1.82M | 123,559 | D | ↗ |
| 2024-12-18 | JENKINS GEORGE M | Director | P-Purchase | A | Common Stock | 4,000 | 12.93 | 51.7K | 180,671 | D | ↗ |
| 2024-12-13 | Wessel Tadd S. | Director | A-Award | A | Stock Option (right to buy) | 24,700 | 13.60 | 335.9K | 24,700 | D | ↗ |
| 2024-12-13 | Martini Jeffrey S | Officer | — | — | Stock Option (right to buy) | 18,541 | 9.79 | 181.5K | 0 | D | ↗ |
| 2024-12-13 | Korenberg Matthew E | Officer | A-Award | A | Stock Option (right to buy) | 167,100 | 13.60 | 2.27M | 167,100 | D | ↗ |
| 2024-12-13 | Kaupinen Wes | Director / Officer / 10% Owner | — | — | Stock Option (right to buy) | 81,459 | 7.53 | 613.4K | 0 | D | ↗ |
| 2024-12-13 | KIRITSY CHRISTOPHER P | Director | A-Award | A | Stock Option (right to buy) | 24,700 | 13.60 | 335.9K | 24,700 | D | ↗ |
| 2024-12-13 | JENKINS GEORGE M | Director | — | — | Common Stock | 0 | 0.00 | — | 11,026 | I | ↗ |
| 2024-12-13 | HERON ELAINE J | Director | — | — | Stock Option (right to buy) | 4,642 | 7.14 | 33.1K | 0 | D | ↗ |
| 2024-12-13 | Goin Kathleen | Officer | — | — | Stock Option (right to buy) | 85,974 | 9.79 | 841.7K | 0 | D | ↗ |
| 2024-12-13 | Dellora Investments LP | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-13 | Davis Todd C | Director | — | — | Common Stock | 0 | 0.00 | — | 112,547 | D | ↗ |
| 2024-12-13 | BVF PARTNERS L P/IL | Other | J-Other | A | Common Stock, $0.001 par value | 234,323 | 0.00 | — | 371,916 | D | ↗ |
Executive team
Top executives
Shares Outstanding
11.84M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Wesley H. Kaupinen President and Chief Executive Officer | 575.0K | — | — | 2.47M | 359.4K | 643.00 | 3.40M | 72.54% | ↗ |
| 2 | 2025 | Kathleen Goin Chief Operating Officer | 481.3K | — | — | 1.31M | 192.5K | — | 1.98M | 65.97% | ↗ |
| 3 | 2025 | Matthew E. Korenberg Chief Financial Officer | 475.3K | — | — | 1.31M | 190.1K | — | 1.97M | 66.25% | ↗ |
| 4 | 2024 | Wesley H. Kaupinen President and Chief Executive Officer | 384.9K | 515.5K | — | 4.53M | — | 643.00 | 5.44M | 83.42% | ↗ |
| 5 | 2024 | Kathleen Goin Chief Operating Officer | 381.4K | 257.5K | — | 485.6K | — | — | 1.12M | 43.18% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wesley H. Kaupinen | Founder, President, Chief Executive Officer & Director | 935.0K | male |
| Kathleen Goin | Chief Operating Officer | 639.0K | female |
| Jeffrey Martini | Chief Scientific Officer | 530.4K | — |
| Emily Cook | Senior Vice President of Clinical Operations | — | female |
| Jason Burdette | SVP of CMC & Technical Operations | — | male |
| Ashley Kline | Chief Commercial Officer | — | female |
| Kent Taylor | Senior Vice President of Sales | — | male |
| Matthew E. Korenberg | Chief Financial Officer & Treasurer | — | male |
| Sarah Foster | Senior Vice President of Human Resources | — | female |
| Vimal Patel | Senior VP of Medical Affairs | — | — |
| Jennifer McDonough | Senior Vice President of Market Access & Patient Services | — | female |
| Bohan Wei | Vice President of Corporate Development & New Product Planning | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PVLA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
